Qantum BioPharma恢复了Nasdaq的守法,与行政主管解决了450k美元的债务。 Quantum BioPharma regains Nasdaq compliance through $450k debt settlement with executives.

Quantum BioPharma重新遵守了Nasdaq的最低投标价格要求,确保其继续列名。 Quantum BioPharma has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing. 该公司与行政主管Anthony Durkacz、Zeeshan Saeed和Donal Carroll完成了450 000美元的债务结算,发行了248 160个B级股份,每股5.44美元。 The company completed $450,000 in debt settlements with executives Anthony Durkacz, Zeeshan Saeed, and Donal Carroll by issuing 248,160 Class B shares at $5.44 each. 这些交易被视为关联方交易,利用加拿大证券法的豁免,避免了少数股东批准的必要性。 These transactions, considered related-party dealings, utilized exemptions from Canadian securities laws, avoiding the need for minority shareholder approval.